Neoadjuvant Chemotherapy Followed by Radiotherapy for Laryngeal Cancer

Ilias Karapantzos¹, Chrysa Karapantzou¹, Paul Zarogoulidis²,Michail Karanikas³, Vasilis Thomaidis⁴, Charalampos Charalampidis⁵

¹Ear, Nose and Throat Department, “Saint Luke” Private Hospital, Panorama, Thessaloniki, Greece; ²Pulmonary Department-Oncology Unit, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; ³General Surgery Department, “Genisis” Private Clinic, Thessaloniki, Greece; ⁴Department of Maxillofacial Surgery, University General Hospital of Alexandroupolis, Alexandroupolis, Greece; ⁵Department of Anatomy, Democritus University of Thrace, Alexandroupolis, Greece.

Corresponding author: Paul Zarogoulidis, M.D, Ph. D. Pulmonary Department-Oncology Unit, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. Fax: 00302310992424 Mobile: 00306977271974 E-mail: pzarog@hotmail.com.

© Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.

Abstract

Early stage of diagnosis is crucial for laryngeal cancer since the organ and function preservation is wanted from the treating physicians. Currently the optimal care of patients with laryngeal cancer is truly multidisciplinary, with progressive advances in surgical, radiation, and medical oncology. Moreover; molecular targeted therapies are on their way.

Take home message: The treatment of patients with laryngeal cancer with systemic therapy represents an opportunity to positively impact functional outcomes with an anatomically and functionally preserved larynx. Future challenges include identification of novel molecular pathways that upregulate tumorigenesis and suppression of these.

Key words: laryngeal cancer, chemotherapy, radiotherapy, molecular therapy.

Neoadjuvant chemotherapy administration prior to definitive irradiation or surgical procedure it has been observed that provides a number of advantages such as the possible eradication of systemic micro metastasis. Moreover; prior to surgery or irradiation chemotherapy is delivered to a tumor which the vessel architecture is unaltered therefore treatment is better delivered. It has been also observed that response to neoadjuvant chemotherapy treatment may also predict the response to subsequent radiation therapy (Figure 1). Neoadjuvant chemotherapy in laryngeal cancer has revolutionized the treatment of this malignant. In the study by Tarpley et al. (1), preoperative methotrexate was firstly administered. Neoadjuvant treatment was further explored in several subsequent clinical trials.(2-9) The largest of these, the Head and Neck Contracts Program, showed that patients with resectable stage III or IV cancer of the oral cavity, larynx and hypopharynx achieved a pathologic CR just only one cycle of preoperative cisplatin and bleomycin chemotherapy. However, it was observed that neoadjuvant chemotherapy failed to demonstrate a benefit in terms of overall survival.(3) Furthermore; Cisplatin and 5-fluorouracil (PF) regimens demonstrated high response rates in patients with previously untreated disease. It has been observed that 30 to 50% of patients achieved clinical complete responses, with pathologic complete response confirmed in approximately two-thirds of the complete responders.(10)
A significant survival advantage was demonstrated among patients who achieved complete clinical and pathological response following platinum and fluorouracil chemotherapy.\(^7,11-13\) In the study by Jacobs et al.\(^ {14}\) and Karp et al.\(^ {15}\) were the first to incorporate this preoperative chemotherapy treatment as a means to select patients for non-surgical definitive treatment. Based on these findings, the first randomized study of organ-preservation therapy for laryngeal cancer was conducted by the Department of Veterans Affairs (VA) Laryngeal Cancer Study Group.\(^ {16}\) Based on this study which started in 1985, a total of 332 patients with either stage III or stage IV laryngeal cancer (57% with laryngeal fixation, and 63% supraglottic tumors) were randomly assigned to one of two treatment strategies. A total laryngectomy followed by radiation and afterwards standard treatment vs chemotherapy followed by either radiotherapy in responding patients or surgery in non-responders. In experimental arm three cycles of induction chemotherapy were included consisting of intravenous cisplatin at 100 mg/m\(^2\) on day 1 and 5-fluorouracil at 1000 mg/m\(^2\)/day over 24 h for five consecutive days.

In order to identify in the best manner, the results three clinical response assessments were performed; A) the first after two cycles of induction chemotherapy administration. If there was not at least a 50% reduction observed in primary tumor size and at least stable disease in the neck, chemotherapy was stopped and surgery was performed. Afterwards postoperative radiotherapy followed. B) If at least a partial response (> 50% shrinkage) was observed after two cycles of chemotherapy administration, patients received a third cycle of induction chemotherapy followed by a second tumor assessment and primary site biopsy. Afterwards definitive radiotherapy (66 -- 76 Gy) followed. C) Finally, after twelve weeks radiotherapy completion, a third tumor assessment by direct laryngoscopy was performed. If the biopsy performed revealed local disease residual disease, then a salvage laryngectomy was performed. If no residual disease was observed, then the patient entered a standardized follow-up schedule. There was a 5-year survival for the two arms of the study and larynx preservation was noted in nearly two-thirds of surviving patients randomized to the induction chemotherapy arm. Also, reduced distant metastasis, were observed, although this observation was not statistically significant. In the publication of the study there was no comparison of the functional quality of life issues between the two arms. However; The study’s analysis in 1998 presented data for swallowing and voice functions. Regarding the voice preservation findings observed in the larynx preservation group were better, while the incidence of swallowing abnormalities were even up to 2 years after treatment in the two treatment arms.\(^ {17}\) At that point, non-surgical therapy became a standard of care for the treatment of locally advanced laryngeal cancer.

The second most important randomized induction therapy trial for larynx preservation was conducted by EORTC (the European Organisation for Research and Treatment of Cancer).\(^ {18}\) In this study a total of 194 patients were randomized to standard total laryngectomy and partial pharyngectomy followed by radiotherapy or to induction platinum and fluorouracil chemotherapy followed by radiotherapy in complete responders. It was observed that the rate of complete clinical response to induction chemotherapy was 54%. Moreover; survival was similar between the study arms, and the functional larynx preservation rate was 48% at 3 years. A third
randomized study involving 68 patients by the GETTEC group with T3 laryngeal cancer patients also supported the concept of larynx preservation.(19) In this study, patients had larynx fixation, but only 31% had a supraglottic tumor. Two-year survival rate was significantly higher in the surgery group than in the chemotherapy group (84 vs 69%). However; 15 of 36 patients (42%) in the chemotherapy group avoided a total laryngectomy. The MACH-NC meta-analysis in these three studies (n = 602) found no significant difference in survival, with larynx preservation in 58% of the surviving patients at 5 years.(20)

In the study by Pointreau et al. (21) a comparison was performed between the effect of three cycles of induction platinum fluorocacil with induction docetaxel/cisplatin/fluorouracil in a larynx-preservation study of 213 laryngeal and hypopharyngeal cancer patients. These patients would otherwise require total laryngectomy. The docetaxel/cisplatin/fluorouracil induction regimen consisted of three planned cycles of intravenous docetaxel at 75 mg/m2 on day 1, cisplatin at 75 mg/m2 on day 1, and 5-fluorouracil at 750 mg/m2/day as a 24-h continuous infusion for 5 days, with each cycle administered at intervals of 21 days. Afterwards, patients which responded to induction chemotherapy received radiotherapy (70 Gy to the tumor volume) with or without additional chemotherapy and non-responders underwent total laryngectomy. Radiotherapy followed with or without additional chemotherapy. It was observed that at 3 years, the laryngeal preservation rate in the taxane (docetaxel) group was significantly higher (70.3 vs 55.7%, p = 0.03) and the response rate was higher in the taxane group (80 vs 59.2%, p = 0.002), however; there was no difference in overall survival. Table 1. (16, 18, 19, 21-24)

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>N. pts Site</th>
<th>Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>VALCSC</td>
<td>332 Larynx</td>
<td>Stage III–IV</td>
</tr>
<tr>
<td>EORTC 24891</td>
<td>202 Hypo pharynx</td>
<td>Stage II–IV</td>
</tr>
<tr>
<td>GETTEC</td>
<td>68 Larynx</td>
<td>Stage II–IV</td>
</tr>
<tr>
<td>GORTEC 2000-01</td>
<td>213 Larynx</td>
<td>Stage III and IV</td>
</tr>
<tr>
<td>EORTC 24954-22950</td>
<td>450 Larynx Hypo pharynx</td>
<td>Stage III and IV</td>
</tr>
<tr>
<td>Posner</td>
<td>166 Larynx</td>
<td>Stage III and IV</td>
</tr>
<tr>
<td>TREMPLIN</td>
<td>153 Larynx</td>
<td>Stage III–IV</td>
</tr>
<tr>
<td>Prades</td>
<td>71 Pyriform sinus cancer</td>
<td>Stage III–IV</td>
</tr>
</tbody>
</table>

Competing Interests
None to declare.

References


